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Abstract 
Background: Research suggests that 90% of patients labeled beta-lactam allergic are able to tolerate penicillins fol-
lowing further assessment. This study aims to define and describe the frequency of true beta-lactam allergy following 
allergy patient evaluation in a predominantly pediatric population.
Methods: 306 primary care patients referred between January 2010 and June 2015 were assessed for a suspected 
beta-lactam allergy. Patient demographics, history and test results were extracted from electronic medical records. 
Testing performed was based on specialist recommendation following review of patient history.
Results: 34% of the study participants had intradermal testing. Oral challenge was given to 96.7% of the sample. 96% 
of patients with a prior history of beta-lactam allergy were advised that they could re-introduce beta-lactam antibiot-
ics following evaluation.
Conclusions: Among patients with a documented beta-lactam allergy or a recent history of a reaction there is a low 
rate of ‘true’ beta-lactam allergy. Consistent evaluation of beta-lactam antibiotic allergies can reduce rates of broad 
spectrum antibiotic prescribing, among other harmful consequences.
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Background
Approximately 10–20% of the general population have 
been labeled as penicillin allergic [1–3]. However, studies 
have clearly documented that over 90% of patients labeled 
allergic are able to tolerate penicillins once assessed [2, 
4]. In addition, recent estimates suggest that the rate of 
penicillin allergy may be decreasing [5], particularly in 
pediatric populations [6]. This may be due to the chang-
ing nature of antibiotic prescription patterns. The reduc-
tion in intravenous penicillin use and the increase in oral 
amoxicillin usage may have reduced true allergies while 
increasing likelihood of viral rashes being inappropriately 
defined as “allergies” [6]. In addition, up to 80% of true 
IgE allergic patients will lose their sensitivity over time 
[7, 8], further contributing to reductions in penicillin 
allergy rates. For example, in a study of 740 patients with 
a history of beta-lactam antibiotic reactions, prevalence 
of positive skin testing was related to time elapsed since 
clinical reaction, in cases that reacted, 93% had a posi-
tive skin test in the past year, while this rate dropped to 
22% in those who were evaluated 10 years or more after 
a reaction [8].
In 2015, the American Academy of Allergy Asthma 
and Immunology (AAAAI) released a statement request-
ing urgent action on the specified harms of erroneously 
labeling patients with penicillin allergy [9]. In particu-
lar, patients reporting penicillin allergies are more likely 
to receive broad-spectrum antibiotics [10] which have 
been linked to higher rates of antibiotic resistance [11] 
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and higher health care costs in the community [12] and 
hospital [13]. Furthermore, while the causation remains 
to be elucidated, penicillin allergies recorded in hospital 
Electronic Health Records correlate strongly with longer 
stays and more iatrogenic infections [14]. While aiming 
to protect patients from adverse drug reactions, inappro-
priately using conservative documentation of penicillin 
allergy confers direct patient harm and is an unnecessary 
cost to the healthcare system [9–14].
This study aims to define and describe the frequency of 
true penicillin allergy among primary care patients evalu-
ated by Allergy and Immunology specialists. It attempts 
to determine whether penicillin allergy could be removed 




This retrospective chart review includes 306 predomi-
nantly pediatric patients referred from community pri-
mary care providers (family physicians or pediatricians) 
to assess a suspected allergy to beta-lactam antibiotics 
by two participating allergy and immunology specialists 
in Winnipeg, Manitoba, Canada. The outcome measures 
used were based on the recommendations made by the 
two participating allergy specialists, both fellows of the 
Royal College of Physicians of Canada. Consultations are 
publicly funded by Manitoba Health with no direct cost 
to the patient.
The inclusion criterion included all patients with a con-
sultation regarding suspected beta-lactam allergy from 
January 2010 to June 2015. Patients were excluded if they 
had incomplete follow-up or were not evaluated for beta-
lactam allergy in the clinic. In addition, intradermal test-
ing and oral challenge were delayed at least 6 weeks after 
a clinical reaction.
Approval was obtained from the Human Research Eth-
ics Board of the University of Manitoba. Individual par-
ticipant consent was not obtained in accordance with 
Canada’s Tri-Council Policy Statement: Ethical Conduct 
for Research Involving Humans and the University of 
Manitoba Research Ethics board policy regarding retro-
spective chart reviews.
Patient data was extracted from electronic medical 
records (JonokeMed 5.5.3) and collated into a spread-
sheet profiling patient age, gender, history and symptoms 
of adverse drug reactions, test results, and consult-
ant recommendations. Queries captured patients with 
a visit to a participating physician between January 1, 
2010 to July 2015. Data was collected in July 2015 by a 
single study author and validated by the consultants 
for accuracy. Patients were selected if they had either a 
visit coded with ICD9 code 995.20 for a drug allergy or a 
billing (fee) tariff corresponding to administration of an 
oral provocation challenge. Documentation from patient 
visits were reviewed for key terms “icil” or “amox” in the 
context of a reaction history or allergy test. All patient 
charts underwent a review for a referral and consultation 
regarding beta-lactam allergy. Relevant chart information 
was extracted from notes relating to initial and follow-up 
appointments.
The recommendations made by the consultants were 
primarily based on results from beta-lactam allergy 
testing, performed by protocols laid out by the Ameri-
can Academy of Allergy, Asthma and Immunology [2]. 
Those with recent adverse drug reaction (ADR) histo-
ries of non-urticarial rash and pruritus were orally chal-
lenged with appropriate dosing of amoxicillin or other 
implicated beta-lactam antibiotic [15]. Patients having 
remote or vague histories and those with histories more 
suggestive of a type I reaction received intradermal test-
ing with later oral drug provocation challenge to the 
implicated beta-lactam antibiotic, if intradermal testing 
was negative. Intradermal testing was done with stand-
ard concentrations of penicilloyl polylysine (6 × 10−5 M), 
benzylpenicillin (10,000 U/mL) and ampicillin (1.25 mg/
mL). Intradermal testing was read 15 min after adminis-
tration. Delayed intradermal testing was not done, how-
ever patients were instructed to contact the clinic should 
any late reactions occur. Patients with histories suggestive 
of serious delayed-type reactions such as serum sickness 
or Stevens-Johnson were not tested and recommended to 
avoid beta-lactam antibiotics.
Results
There were 335 unique patient records meeting the study 
criteria. A total of 29 patients were excluded from the 
study due to pending test results (25 patients), refusal of 
oral challenge (3 patients) and a history of chronic urti-
caria with incomplete testing (1 patient). A total of 306 
patients were considered as part of the study. Figure  1 
displays the study inclusion criteria.
Study population
303 (99%) of the patients were referred by their primary 
care providers (family physicians, pediatricians or nurse 
practitioner) the remainder were referred by an Emer-
gency Department or other specialist providers. The 
sample was evenly distributed between the genders, 
with males being slightly younger on average at testing 
(Table  1). The mean age of the patient population was 
11.6 years (standard deviation 17.3 years) and the median 
age was 6.0  years. Our sample was mostly pediatric 
patients although the large standard deviation reflects a 
small number of adult and older patients who skew the 
distribution to a bimodal pattern.
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Patients had a variety of clinical reactions upon beta-
lactam antibiotic exposure with the most prevalent “non-
urticarial skin reactions”, “Urticarial skin reactions” and 
“multi-systemic complaints”. Table  2 outlines patient 
clinical reactions. Average time elapsed between drug 
reaction and allergological work up was 5.4 years. A total 
of 106 patients (34%) had intradermal testing (see Fig. 2). 
Oral challenge was given to 96.7% of the sample (296 
patients), 64.5% (191 patients) of those patients had a 
history inconsistent with type 1 allergy and therefore did 
not receive prior skin testing. Type 1 allergy was found 
among 0.7% of the sample: 0.3% (1 patient) had a posi-
tive intradermal test and 0.3% (1 patient) with a negative 
intradermal test had a positive oral challenge poten-
tially consistent with a type 1 reaction. This reaction 
(acute onset abdominal pain and emesis within an hour 
of a dose of amoxicillin) was different than the reaction 
that this patient initially presented with (acute urticaria 
within one hour after a dose of amoxicillin), and occurred 
in a toddler. 
Additionally, 1.3% of the sample (4 patients) had a 
positive delayed oral challenge (delayed maculo-papular 
Fig. 1 Inclusion criteria
Table 1 Patient demographics
Total Male Female
Number 306 (100%) 150 (49%) 156 (51%)
Age (Mean, SD) 11.6, 17.3 9.5, 16.3 13.6, 18.0
 (Mode) 1 2 3
 (Q1, Q2, Q3) 3, 6, 11 2, 5, 10 3, 7, 14
 (Extremes) 0, 89 0, 89 0, 82
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exanthems) after negative intradermal testing. In addi-
tion, 1.9% (6 patients) were advised to avoid beta-lactams 
without testing based on a clinical history suggestive of a 
serious delayed reaction (Table 3).
After completed consultation, 2/306 patients (0.7%, 
CI95 0–2.6%) were considered to be at increased risk 
of future IgE-mediated reactions (one due to positive 
intradermal testing and one due to a reaction with oral 
challenge). In addition, 10 patients (3.3%, CI95 1.7–6.0%) 
were considered to be at increased risk of delayed reac-
tions (4 of whom had delayed maculopapular exanthems 
with oral challenge, and 6 of whom had no testing due 
to history suggestive of a serious delayed reaction such 
as serum sickness). Overall, 294 (96.1%, CI95 93.2–97.9%) 
of those evaluated were advised that they could safely 
use beta-lactam antibiotics in the future. It is unknown 
whether these patients have used beta-lactam antibiotics 
since their allergy evaluation.
Discussion
This current study found that among patients with a 
label of beta-lactam allergy there was a low rate of true 
allergy observed. The overall rate of false positive reports 
of penicillin allergy was high with 96.1% of patients with 
a prior history of beta-lactam allergy advised that they 
could safely re-introduce beta-lactam antibiotics. The 
rate of true penicillin allergy in this sample was much 
lower than in other studies of referral populations, which 
have documented 10–20% true allergy among patients 
labeled as beta-lactam allergic [1–3]. Consistent evalu-
ation of patients with a history of beta-lactam allergy 
could reduce the use of broad-spectrum antibiotics if 
performed before labelling patients with a presumed 
allergy. This practice could significantly reduce the risk of 
patients receiving broad spectrum antibiotics inappropri-
ately, which is thought to contribute to antibiotic resist-
ance. The Centers for Disease Control and Prevention 
report that in the United States there are about 2 million 
illnesses and 23,000 deaths caused by antibiotic-resistant 
bacteria [16]. The AAAAI has urged more aggressive use 
of drug allergy testing to reduce increasing rates of anti-
biotic resistance [9].
Previous studies have reported that 9–11% of patients 
have systemic reactions when skin testing is performed 
to beta-lactams [17, 18]. In a recent study 2.6% of beta-
lactam allergic children reported mild to moderate reac-
tions to skin testing [19]. Our study, in contrast, noted no 
systemic reactions to skin testing (although several pos-
sible explanations could exist for this finding).
In the current study, no patient with negative intrader-
mal testing had a subsequent anaphylactic reaction on 
oral challenge. One patient had emesis and abdominal 
pain, which was considered to be potentially indicative of 
a type I reaction as it was shortly following oral challenge 
in a toddler. In addition, 1.3% (4 patients) had a delayed 
reaction on oral challenge, despite negative intradermal 
testing.
A possible limitation of our study was the lack of 
delayed intradermal readings and use of patch test-
ing. For delayed beta-lactam reactions, some stud-
ies have suggested that either or both of these methods 




Unknown skin reaction (remote Hx) 18
Non-urticarial skin reactions 151
Urticarial skin reactions 76
Skin peeling noted 2
Multi-systemic complaints 50
 Skin rash with fever/malaise 5
 Describing open sores 1
 Skin rash with GI complaints 6
 Edema or difficulty breathing 34
 Myalgia or joint swelling 5
History unknown 8
Fig. 2 Patient evaluation
Table 3 Allergy type
Consensus allergy Number Percent (%) CI95 (%)
Type 1 2 0.7 0–2.6
Type 2 0 – –
Type 3 (serum sickness) 5 1.6 0.5–3.9
Type 4 (mild) 4 1.3 0.3–3.5
Type 4 (SJS) 1 0.3 0–2.1
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may provide some value [20–22]. In fact, some clinical 
management reviews recommend delayed intradermal 
testing and/or atopy patch testing in the evaluation of 
non-immediate reactions to penicillins [20]. Recent stud-
ies have also used 5-day drug provocation testing to eval-
uate non-immediate reactions to amoxicillin [23].
Our study followed the AAAAI practice parameter 
which recommends avoidance of testing and oral chal-
lenges in patients with a history of severe cutaneous 
adverse drug reaction such as serum sickness or Stevens 
Johnsons. Interestingly, other studies have noted a low 
correlation between reaction history for severe adverse 
drug reactions and subsequent risk of reactivity [24].
Low consensus between confirmed beta-lactam allergy 
and documented history of a beta-lactam allergy has 
implications for the implementation of a national agenda 
around interoperable digital patient health records 
among health care settings [25]. Interoperability is pro-
posed to improve patient care and outcomes [25] but 
could present problems if erroneous clinical information 
is being shared due to the lack of patient record accu-
racy. Health care providers and administrators should be 
aware of the risk of sharing potentially erroneous patient 
data. These findings suggest the need to more actively 
incorporate strategies into primary care practices to 
proactively identify patients who are likely mislabeled 
with beta-lactam allergy to avoid the harms of antibiotic 
avoidance.
This study tracked consultation recommendations as 
oppose to more objective test results which was expected 
to produce a more reliable measure of the effects of peni-
cillin allergy consultation in determining rates of valid 
avoidance of beta-lactams. Assessing the practices of 
only two physicians operating within one clinic can cre-
ate the potential for bias related to clinical decision mak-
ing. Our sample is primarily pediatric patients and it may 
not apply to other populations without assessment of 
local prevalence and demographics of ‘penicillin allergy’. 
Furthermore, this sample is dependent on the referral 
of primary care physicians so it is uncertain if certain 
patient populations with greater or lesser risk of mislabe-
ling are being referred or not.
Conclusion
Our findings demonstrate that a profound majority of 
pediatric patients in the community who had a consul-
tation with an allergist erroneously consider themselves 
allergic prior to evaluation. Meanwhile, the risks of avoid-
ing these targeted and often effective antibiotics have 
severe consequences for patients and the population. 
More research is needed to evaluate the prevalence of 
potential mislabeling of beta-lactam “allergy” and deter-
mine the true rate of type 1 reaction in the population.
Information regarding allergies that become part of 
patient records are primarily self-reported. As patients 
have increasing health literacy, more discussion will 
be required to clarify these labels. In addition, primary 
care providers need to be better informed as to when to 
refer patients for consultation with an allergist and how 
to properly record drug reactions. These types of initia-
tives are increasingly important as health information is 
shared across the system in systems that will eventually 
be interoperable.
This study highlights the widespread mislabeling of pri-
mary care patients with beta-lactam antibiotic allergy in a 
predominantly pediatric population and suggests urgent 
attention be paid to identifying these patients in order to 
determine who are truly allergic.
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